AR118823A1 - Uso de cannabidiol en el tratamiento del complejo de esclerosis tuberosa - Google Patents
Uso de cannabidiol en el tratamiento del complejo de esclerosis tuberosaInfo
- Publication number
- AR118823A1 AR118823A1 ARP200101225A ARP200101225A AR118823A1 AR 118823 A1 AR118823 A1 AR 118823A1 AR P200101225 A ARP200101225 A AR P200101225A AR P200101225 A ARP200101225 A AR P200101225A AR 118823 A1 AR118823 A1 AR 118823A1
- Authority
- AR
- Argentina
- Prior art keywords
- cbd
- equal
- concentration less
- thc
- cannabidiol
- Prior art date
Links
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 title abstract 10
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 title abstract 10
- 229950011318 cannabidiol Drugs 0.000 title abstract 10
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 title abstract 10
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 title abstract 10
- 208000026911 Tuberous sclerosis complex Diseases 0.000 title abstract 3
- 229960003965 antiepileptics Drugs 0.000 abstract 3
- 229930003827 cannabinoid Natural products 0.000 abstract 2
- 239000003557 cannabinoid Substances 0.000 abstract 2
- 229940065144 cannabinoids Drugs 0.000 abstract 2
- CYQFCXCEBYINGO-SJORKVTESA-N (6as,10ar)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol Chemical compound C1=C(C)CC[C@@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-SJORKVTESA-N 0.000 abstract 1
- WBRXESQKGXYDOL-DLBZAZTESA-N 5-butyl-2-[(1r,6r)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]benzene-1,3-diol Chemical compound OC1=CC(CCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 WBRXESQKGXYDOL-DLBZAZTESA-N 0.000 abstract 1
- GKVOVXWEBSQJPA-UONOGXRCSA-N 5-methyl-2-[(1r,6r)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]benzene-1,3-diol Chemical compound CC(=C)[C@@H]1CCC(C)=C[C@H]1C1=C(O)C=C(C)C=C1O GKVOVXWEBSQJPA-UONOGXRCSA-N 0.000 abstract 1
- REOZWEGFPHTFEI-JKSUJKDBSA-N Cannabidivarin Chemical compound OC1=CC(CCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 REOZWEGFPHTFEI-JKSUJKDBSA-N 0.000 abstract 1
- 241001471082 Colocasia bobone disease-associated cytorhabdovirus Species 0.000 abstract 1
- 206010010904 Convulsion Diseases 0.000 abstract 1
- 239000001961 anticonvulsive agent Substances 0.000 abstract 1
- REOZWEGFPHTFEI-UHFFFAOYSA-N cannabidivarine Natural products OC1=CC(CCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 REOZWEGFPHTFEI-UHFFFAOYSA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
La presente se refiere al uso de una preparación de cannabidiol (CBD) para utilizar en el tratamiento de crisis asociadas con el complejo de esclerosis tuberosa (TSC; del inglés, Tuberous Sclerosis Complex). Preferentemente el CBD utilizado se encuentra en forma de un CBD purificado derivado botánicamente, que comprende un porcentaje mayor o igual al 98% (p/p) de CBD y menor o igual al 2% (p/p) de otros cannabinoides. Los otros cannabinoides presentes son THC a una concentración menor o igual al 0,1% (p/p); CBD-C1 a una concentración menor o igual al 0,15% (p/p); CBDV a una concentración menor o igual al 0,8% (p/p); y CBD-C4 a una concentración menor o igual al 0,4% (p/p). El CBD purificado derivado botánicamente también comprende preferentemente una mezcla tanto de trans-THC como de cis-THC. Como alternativa, se utiliza un CBD producido sintéticamente. En el uso el CBD se proporciona de forma concomitante con otro(s) fármaco(s) antiepiléptico(s) (FAE; en inglés, AED). Como alternativa, se puede formular el CBD para la administración separada, secuencial o simultáneamente con uno o más FAE o la combinación se puede proporcionar en una forma de administración única.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1906261.1A GB2583526A (en) | 2019-05-03 | 2019-05-03 | Use of cannabidiol in the treatment of tuberous sclerosis complex |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR118823A1 true AR118823A1 (es) | 2021-11-03 |
Family
ID=67385024
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200101225A AR118823A1 (es) | 2019-05-03 | 2020-04-30 | Uso de cannabidiol en el tratamiento del complejo de esclerosis tuberosa |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP3962467A1 (es) |
| JP (1) | JP2022531003A (es) |
| KR (1) | KR20220007089A (es) |
| CN (1) | CN113795245A (es) |
| AR (1) | AR118823A1 (es) |
| AU (1) | AU2020267908A1 (es) |
| BR (1) | BR112021021029A2 (es) |
| CA (1) | CA3136274A1 (es) |
| GB (1) | GB2583526A (es) |
| IL (1) | IL287704A (es) |
| MX (1) | MX2021013285A (es) |
| TW (1) | TW202108133A (es) |
| WO (1) | WO2020225540A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202002754D0 (en) * | 2020-02-27 | 2020-04-15 | Gw Res Ltd | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
| GB2601755A (en) * | 2020-12-08 | 2022-06-15 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with epilepsy syndromes |
| US20250025482A1 (en) * | 2021-07-28 | 2025-01-23 | GW Research Limited | Use of cannabidiol in the treatment of epilepsy |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2471523A (en) | 2009-07-03 | 2011-01-05 | Gw Pharma Ltd | Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy |
| GB2487712B (en) | 2011-01-04 | 2015-10-28 | Otsuka Pharma Co Ltd | Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy |
| GB2514054A (en) | 2011-09-29 | 2014-11-12 | Gw Pharma Ltd | A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
| GB2531281A (en) * | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| GB2531282A (en) * | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2564383B (en) * | 2017-06-23 | 2021-04-21 | Gw Res Ltd | Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex |
| GB201806953D0 (en) * | 2018-04-27 | 2018-06-13 | Gw Res Ltd | Cannabidiol Preparations |
-
2019
- 2019-05-03 GB GB1906261.1A patent/GB2583526A/en not_active Withdrawn
-
2020
- 2020-04-30 AR ARP200101225A patent/AR118823A1/es not_active Application Discontinuation
- 2020-04-30 TW TW109114571A patent/TW202108133A/zh unknown
- 2020-05-01 WO PCT/GB2020/051080 patent/WO2020225540A1/en unknown
- 2020-05-01 KR KR1020217039505A patent/KR20220007089A/ko active Pending
- 2020-05-01 MX MX2021013285A patent/MX2021013285A/es unknown
- 2020-05-01 EP EP20724924.4A patent/EP3962467A1/en not_active Withdrawn
- 2020-05-01 AU AU2020267908A patent/AU2020267908A1/en not_active Abandoned
- 2020-05-01 BR BR112021021029A patent/BR112021021029A2/pt not_active Application Discontinuation
- 2020-05-01 CA CA3136274A patent/CA3136274A1/en active Pending
- 2020-05-01 JP JP2021565086A patent/JP2022531003A/ja active Pending
- 2020-05-01 CN CN202080033014.7A patent/CN113795245A/zh active Pending
-
2021
- 2021-10-31 IL IL287704A patent/IL287704A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3962467A1 (en) | 2022-03-09 |
| GB201906261D0 (en) | 2019-06-19 |
| CN113795245A (zh) | 2021-12-14 |
| BR112021021029A2 (pt) | 2021-12-14 |
| AU2020267908A1 (en) | 2021-11-11 |
| GB2583526A (en) | 2020-11-04 |
| MX2021013285A (es) | 2021-11-17 |
| IL287704A (en) | 2021-12-01 |
| JP2022531003A (ja) | 2022-07-05 |
| TW202108133A (zh) | 2021-03-01 |
| WO2020225540A1 (en) | 2020-11-12 |
| CA3136274A1 (en) | 2020-11-12 |
| KR20220007089A (ko) | 2022-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR118823A1 (es) | Uso de cannabidiol en el tratamiento del complejo de esclerosis tuberosa | |
| CL2018003452A1 (es) | Formulaciones nasales semi-sólidas y líquidas visuales de cannabinoides. | |
| MX2021008702A (es) | Uso de cannabinoides en el tratamiento de las comorbilidades asociadas a la epilepsia. | |
| MX2020005147A (es) | Uso de cannabinoides en el tratamiento de convulsiones asociadas al sindrome de lennox-gastaut. | |
| MX2021014158A (es) | Uso de cannabidiol en el tratamiento de espasmos epilepticos. | |
| MX2021006270A (es) | Uso de cannabidiol en el tratamiento del complejo de esclerosis tuberosa. | |
| MX2021006094A (es) | Uso de cannabinoides en el tratamiento de epilepsia. | |
| MX2020003415A (es) | Compuestos de benzoxacepina oxazolidinona y métodos de uso. | |
| CO6331301A2 (es) | Combinaciones y metodos para administracion subcutanea de inmunoglobulina y hialuronidasa | |
| BR112018008684A2 (pt) | formulações de toxina botulínica injetáveis e processos de uso das mesmas com longa duração do efeito terapêutico ou cosmético | |
| CO2019007409A2 (es) | Derivados de la pirimidin enona tricíclica para la inhibición de rorγ y otros usos | |
| AR048705A1 (es) | Composiciones farmaceuticas para el tratamiento de los trastornos sexuales ii | |
| DOP2014000159A (es) | Composiciones enriquecidas con dpa de ácidos grasos omega 3 poliinsaturados en forma de ácido libre | |
| CO2024001285A2 (es) | Compuestos tricíclicos como inhibidores de kras | |
| PE20142363A1 (es) | Usos y articulo de fabricacion que incluye el inhibidor de la dimerizacion de her2 pertuzumab | |
| CO6311008A2 (es) | Composicion farmaceutica que comprende un agente que activa las celulas t regulatorias cd4+cd25+ | |
| CO6311007A2 (es) | Composicion farmaceutica que comprende un agente que activa las celulas t regulatorias cd4+cd25+, efectiva a dosis bajas | |
| CL2021002646A1 (es) | Métodos y composiciones para su uso en el tratamiento del cáncer sin efectos psicosactivos | |
| PE20200338A1 (es) | Composiciones cannabinoides novedosas y metodos para tratar la epilepsia infantil | |
| DOP2013000224A (es) | Uso de 2,3-dihidroimidazo[1,2-c] quinazolinas sustituidas. | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| CO5640037A2 (es) | Derivados de la quinazolina para el tratamiento del cancer | |
| UY29802A1 (es) | Análogos de la feniletilamina y su uso en el tratamiento del glaucoma | |
| AR045943A1 (es) | Formulaciones de acetonido de triamcinolona y acetato de anecortave para inyeccion | |
| PE20150226A1 (es) | Agentes terapeuticos para administracion subcutanea optimizados |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |